Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 and chemotherapy in malignant mesothelioma
NCT07131345Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2025
- Primary completion
- Oct 2026
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in malignant mesothelioma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT07131345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07131345.